Viridian Therapeutics, Inc.’s VRDN share price has dipped by 6.94%, which has investors questioning if this is right time to ...

A $42 million project promising nearly 100 units of affordable housing broke ground in Tacoma this week as part of a push to ...

4Front's default includes four leases, notably impacting its flagship 250,000-square-foot facility in Matteson, Illinois. The ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the ...

Viridian Therapeutics (NASDAQ:VRDN) shares shot up 25% in early trading Monday after the company reported positive topline results from a Phase 3 study of its drug veligrotug in the treatment of ...

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian ...

Investors eyeing a purchase of Viridian Therapeutics Inc (Symbol: VRDN) stock, but tentative about paying the going market price of $15.70/share, might benefit from considering selling puts among ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viridian Therapeutics (VRDN) announced the appointment of Jeff Ajer to its Board of Directors. Ajer most recently served as the Executive Vice ...